Diabetech
The latest in diabetes tech and research—and what it means for you
Connect
A new CGM deal moves PharmaSens one step closer to creating a fully self-contained insulin pump and CGM.
The pump currently in development allows users to change sites without a phone—potentially reshaping the tubeless landscape and pushing rivals to move faster.
Smartwatch bolusing, advanced occlusion detection, and CGM integration set the stage for Sequel Med Tech’s game-changing debut.
Tandem, Beta Bionics, Sequel Med Tech, and Ypsomed are the first to announce integration plans for Abbott’s dual-analyte sensor with more expected.
Abbott’s flagship CGM now powers Tandem’s Control-IQ+ system—with more pump integrations and a ketone sensor on the horizon.
After hearing your stories, we brought in experts—and spoke to Dexcom—to unpack what’s going on with Dexcom G7 sensor failures.
With seamless site changes and fast software iteration, Beta Bionics’ upcoming patch pump could challenge the pace and expectations of the tubeless pump market.
Dexcom's latest CGM is now supported on the Omnipod 5 iPhone App.
This early pioneer was certain CGM technology would improve patient lives when others doubted her.
Tandem Diabetes is already telling patients its smartphone app to control the Mobi insulin pump will arrive by the end of 2025.
After three years with Omnipod, a tubed pump taught me something new about tech—and myself
The diabetes division will separate from its parent company. Could this unlock faster innovation—or is it more of the same with a new name?
